FCGR3A and neoplasm: Furthermore, after recognizing and binding to the tumor antigen, the tumor antigen-specific antibody binds to CD16 NK cell surface receptor, which can also enhance the activation signal of NK and trigger antibody-dependent cytotoxicity (64).